Cardlytics (CDLX) Financials

Cardlytics logo
$1.27 -0.02 (-1.16%)
As of 12:25 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Annual Income Statements for Cardlytics

Annual Income Statements for Cardlytics

This table shows Cardlytics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-77 -25 -53 -17 -55 -129 -465 -135 -189 -103
Consolidated Net Income / (Loss)
-76 -20 -53 -17 -55 -129 -465 -135 -189 -103
Net Income / (Loss) Continuing Operations
-76 -20 -53 -17 -55 -129 -465 -135 -189 -103
Total Pre-Tax Income
-76 -20 -53 -17 -55 -136 -467 -135 -189 -103
Total Operating Income
-56 -17 -41 -17 -54 -123 -458 -136 -195 -102
Total Gross Profit
113 130 151 210 187 267 299 309 278 233
Total Revenue
113 130 151 210 187 267 299 309 278 233
Operating Revenue
113 130 151 210 187 267 299 309 278 233
Total Cost of Revenue
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses
169 147 192 228 241 390 756 445 474 335
Selling, General & Admin Expense
21 20 34 37 47 66 81 59 56 47
Marketing Expense
31 32 42 44 45 66 75 57 53 39
Research & Development Expense
14 12 16 12 18 38 54 51 50 40
Depreciation Expense
4.22 3.03 3.28 4.54 7.83 30 38 26 26 25
Other Operating Expenses / (Income)
98 80 96 131 124 190 55 180 158 124
Impairment Charge
- - - - 0.00 0.00 453 71 132 59
Total Other Income / (Expense), net
-19 -2.54 -12 0.18 -1.50 -14 -8.93 0.97 6.20 -1.67
Interest Expense
6.17 8.24 3.26 0.55 3.05 13 0.00 0.00 -13 0.00
Interest & Investment Income
- - - - - - -2.56 -2.34 -5.55 -7.92
Other Income / (Expense), net
-13 5.70 -8.86 0.73 1.55 -1.27 -6.38 3.30 -1.27 6.25
Income Tax Expense
0.00 0.00 0.00 0.00 0.00 -7.86 -1.45 0.00 0.00 0.00
Basic Earnings per Share
($32.48) ($7.86) ($2.79) ($0.72) ($2.04) ($3.99) ($13.92) ($3.69) ($3.91) ($1.95)
Weighted Average Basic Shares Outstanding
2.36M 3.23M 19.06M 23.75M 27.21M 32.20M 33.42M 36.49M 48.36M 53.11M
Diluted Earnings per Share
($32.48) ($7.86) ($2.79) ($0.72) - - ($13.92) ($3.69) ($3.91) ($1.95)
Weighted Average Diluted Shares Outstanding
2.36M 3.23M 19.06M 23.75M 27.21M 32.20M 33.42M 36.49M 48.36M 53.11M
Weighted Average Basic & Diluted Shares Outstanding
2.36M 3.23M 19.06M 23.75M 27.21M 32.20M 33.61M 44.11M 52.09M 55.05M

Quarterly Income Statements for Cardlytics

This table shows Cardlytics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
-24 -4.26 -145 -16 -13 -9.28 -73 -8.25 -4.48 -15 -8.95
Consolidated Net Income / (Loss)
-24 -4.26 -145 -16 -13 -9.28 -73 -8.25 -4.48 -15 -8.95
Net Income / (Loss) Continuing Operations
-24 -4.26 -145 -16 -10 -6.06 -70 -8.25 -14 -8.66 -7.43
Total Pre-Tax Income
-24 -4.26 -145 -16 -10 -6.06 -70 -8.25 -14 -8.66 -7.43
Total Operating Income
-23 -16 -149 -8.32 -11 -9.57 -66 -6.09 -8.27 -5.44 -5.42
Total Gross Profit
68 70 67 74 56 58 47 56 34 37 33
Total Revenue
68 70 67 74 56 58 47 56 34 37 33
Operating Revenue
68 70 67 74 56 58 47 56 34 37 33
Total Cost of Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses
90 85 216 82 68 68 113 62 43 42 38
Selling, General & Admin Expense
14 16 12 14 13 12 10 9.73 8.28 7.86 7.09
Marketing Expense
14 14 13 11 10 8.94 6.55 7.52 6.76 6.61 6.68
Research & Development Expense
13 13 13 9.90 10 9.87 7.47 7.97 6.43 5.54 3.71
Depreciation Expense
6.25 6.53 6.97 5.94 4.35 4.24 4.45 6.21 3.94 4.06 4.18
Other Operating Expenses / (Income)
43 35 39 42 35 32 26 31 17 18 17
Impairment Charge
- - 132 - - - 59 - - - 0.00
Other Special Charges / (Income)
- 0.00 0.00 - -5.35 0.20 0.32 - 0.00 0.00 0.00
Total Other Income / (Expense), net
-1.45 12 3.36 -7.28 0.80 3.51 -3.82 -2.16 -5.52 -3.22 -2.01
Interest & Investment Income
- -1.56 -1.48 - -1.83 -1.94 -2.01 - -3.82 -3.38 -2.29
Other Income / (Expense), net
-0.63 0.10 4.84 -5.58 2.63 5.45 -1.81 -0.02 -1.71 0.17 0.29
Income Tax Expense
- - - - 0.00 0.00 0.00 - 0.00 0.00 0.00
Net Income / (Loss) Discontinued Operations
- - - - -2.96 -3.22 -2.41 - 9.32 -6.22 -1.52
Weighted Average Basic Shares Outstanding
43.25M 49.06M 50.03M 48.36M 51.86M 5.28M 5.35M 53.11M 54.90M 5.76M 5.90M
Weighted Average Diluted Shares Outstanding
43.25M 49.06M 50.03M 48.36M 51.86M 5.28M 5.35M 53.11M 54.90M 5.76M 5.90M
Weighted Average Basic & Diluted Shares Outstanding
48.78M 49.84M 50.82M 52.09M 52.50M 53.24M 54.06M 55.05M 57.61M 5.89M 6.10M

Annual Cash Flow Statements for Cardlytics

This table details how cash moves in and out of Cardlytics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
-4.23 -1.99 39 45 189 -60 -112 -30 -26 -17
Net Cash From Operating Activities
-32 -22 -19 11 -7.60 -39 -54 -0.19 -8.82 9.29
Net Cash From Continuing Operating Activities
-32 -22 -19 11 -7.60 -39 -54 -0.19 -8.82 9.29
Net Income / (Loss) Continuing Operations
-76 -20 -53 -17 -55 -129 -465 -135 -189 -103
Consolidated Net Income / (Loss)
-76 -20 -53 -17 -55 -129 -465 -135 -189 -103
Depreciation Expense
4.22 3.03 3.28 4.54 7.83 30 38 26 26 25
Amortization Expense
6.36 9.08 4.23 0.10 11 20 7.79 4.70 3.82 3.69
Non-Cash Adjustments To Reconcile Net Income
46 -0.34 30 16 33 45 506 116 167 78
Changes in Operating Assets and Liabilities, net
-14 -14 -3.43 7.49 -3.75 -5.32 -139 -12 -16 5.82
Net Cash From Investing Activities
-2.55 -1.65 -7.34 -11 -10 -507 -16 -10 -19 -15
Net Cash From Continuing Investing Activities
-2.55 -1.65 -7.34 -11 -10 -507 -16 -10 -19 -15
Purchase of Property, Plant & Equipment
-2.47 -1.59 -7.32 -11 -10 -12 -13 -12 -19 -16
Divestitures
- - - - - 0.00 0.00 2.33 0.55 0.48
Net Cash From Financing Activities
31 22 65 44 206 486 -40 -20 1.44 -11
Net Cash From Continuing Financing Activities
31 22 65 44 206 486 -40 -20 1.44 -11
Repayment of Debt
-34 -0.24 -53 -47 -0.41 -0.20 -0.21 -0.03 -205 -62
Repurchase of Common Equity
-1.67 -2.67 -1.95 -0.20 0.00 -0.19 -40 0.00 -0.31 0.00
Issuance of Debt
66 13 47 0.00 223 0.00 0.00 30 173 56
Issuance of Common Equity
0.28 0.23 72 91 10 486 0.38 0.06 49 0.00
Other Financing Activities, net
- - 0.00 0.00 -26 0.00 0.00 -50 -14 -5.00
Other Net Changes in Cash
- - - - - - - - - 0.26
Cash Interest Paid
- 0.87 9.73 - 0.06 2.33 2.38 4.24 6.12 9.26

Quarterly Cash Flow Statements for Cardlytics

This table details how cash moves in and out of Cardlytics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
5.94 -27 -4.26 -1.39 -14 -5.30 -2.78 4.76 -13 -7.63 1.91
Net Cash From Operating Activities
-18 4.43 1.39 2.98 -6.71 1.23 1.76 13 -5.64 -8.60 -5.90
Net Cash From Continuing Operating Activities
-18 4.43 1.38 2.98 -6.71 1.23 1.76 13 -5.64 -8.60 -5.90
Net Income / (Loss) Continuing Operations
-24 -4.26 -145 -16 -13 -9.28 -73 -8.25 -4.48 -15 -8.95
Consolidated Net Income / (Loss)
-24 -4.26 -145 -16 -13 -9.28 -73 -8.25 -4.48 -15 -8.95
Depreciation Expense
6.25 6.53 6.97 5.94 6.29 6.28 6.47 6.21 4.42 4.06 4.18
Amortization Expense
0.99 0.93 0.94 -12 1.04 1.04 0.91 0.70 0.65 0.64 0.62
Non-Cash Adjustments To Reconcile Net Income
13 1.81 135 29 1.37 3.44 67 5.87 -6.33 4.40 1.69
Changes in Operating Assets and Liabilities, net
-14 -0.58 3.58 -4.75 -2.12 -0.24 -0.30 8.48 0.10 -2.81 -3.45
Net Cash From Investing Activities
-4.75 -4.66 -5.26 -4.09 -3.90 -4.66 -4.46 -2.28 -2.30 21 -2.17
Net Cash From Continuing Investing Activities
-4.75 -4.66 -5.26 -4.09 -3.90 -4.66 -4.46 -2.28 -2.30 21 -2.20
Purchase of Property, Plant & Equipment
-4.75 -4.86 -5.26 -4.44 -4.10 -4.66 -4.46 -2.56 -2.30 -2.11 -2.20
Net Cash From Financing Activities
28 -26 -0.39 -0.20 -3.03 -2.06 -0.01 -6.02 -5.02 -20 9.97
Net Cash From Continuing Financing Activities
28 -26 -0.39 -0.20 -3.03 -2.06 -0.01 -6.02 -5.02 -20 9.97
Repayment of Debt
-0.24 -205 -0.27 -0.21 -0.03 -0.06 -50 -12 -10 -20 -0.03
Issuance of Debt
- - - - 0.00 - 50 6.00 5.00 - 10
Cash Interest Paid
1.86 0.34 0.25 3.67 0.25 3.69 0.84 4.48 0.63 3.95 0.35

Annual Balance Sheets for Cardlytics

This table presents Cardlytics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
101 154 224 423 1,264 691 574 393 286
Total Current Assets
75 124 196 386 359 250 224 178 137
Cash & Equivalents
21 40 104 293 233 122 92 66 49
Accounts Receivable
51 61 85 87 117 120 126 107 85
Prepaid Expenses
2.12 3.96 5.78 5.69 7.98 7.98 6.10 5.34 3.21
Other Current Nonoperating Assets
- - - - - - - - 0.42
Plant, Property, & Equipment, net
7.32 10 14 14 11 5.92 3.32 2.60 1.93
Total Noncurrent Assets
19 19 14 23 894 435 347 212 146
Goodwill
- - - 0.00 743 353 277 159 110
Intangible Assets
0.96 2.00 4.20 6.75 139 73 60 45 19
Other Noncurrent Operating Assets
18 17 10 16 13 9.16 10 7.99 5.96
Other Noncurrent Nonoperating Assets
- - - - - - - - 11
Total Liabilities & Shareholders' Equity
101 154 224 423 1,264 691 574 393 286
Total Liabilities
113 102 81 265 573 480 439 323 292
Total Current Liabilities
42 52 78 81 327 249 171 149 78
Accounts Payable
1.55 2.10 1.23 1.36 4.62 3.77 4.43 3.69 2.66
Accrued Expenses
4.62 4.39 6.02 5.52 20 21 9.59 7.18 7.13
Current Deferred Revenue
0.13 0.35 1.13 0.35 3.28 1.75 2.41 2.15 2.54
Current Employee Benefit Liabilities
4.64 5.94 8.19 7.58 12 10 12 5.49 6.04
Other Current Liabilities
31 39 62 66 288 212 143 85 58
Other Current Nonoperating Liabilities
- - - - - - - - 1.66
Total Noncurrent Liabilities
71 50 2.65 184 246 231 268 174 214
Long-Term Debt
57 47 0.01 174 184 226 258 168 209
Other Noncurrent Operating Liabilities
10 - 0.00 10 61 4.31 11 6.03 4.75
Other Noncurrent Nonoperating Liabilities
- - - - - - - - 0.09
Total Equity & Noncontrolling Interests
-209 52 143 157 691 212 135 70 -6.51
Total Preferred & Common Equity
-209 52 143 157 691 212 135 70 -6.51
Total Common Equity
-209 52 143 157 691 212 135 70 -6.51
Common Stock
59 371 481 551 1,213 1,183 1,244 1,367 1,400
Retained Earnings
-268 -321 -339 -394 -523 -977 -1,111 -1,301 -1,404
Accumulated Other Comprehensive Income / (Loss)
1.07 1.99 1.31 -0.19 0.49 5.60 2.47 3.60 -2.00

Quarterly Balance Sheets for Cardlytics

This table presents Cardlytics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
635 569 534 399 369 361 293 264 235 229
Total Current Assets
206 218 185 183 157 150 141 129 101 96
Cash & Equivalents
90 98 71 67 52 47 44 36 28 30
Accounts Receivable
108 111 107 110 99 97 91 66 70 62
Prepaid Expenses
7.26 9.49 6.72 6.79 5.33 7.04 5.35 2.97 2.53 4.16
Other Current Nonoperating Assets
- - - - - - - 0.00 0.00 0.00
Plant, Property, & Equipment, net
3.01 2.91 3.08 2.85 2.47 2.39 2.21 1.74 1.62 1.48
Total Noncurrent Assets
426 348 346 213 210 208 150 134 132 131
Goodwill
353 277 277 159 159 159 110 110 110 110
Intangible Assets
67 59 59 45 44 43 33 18 17 15
Other Noncurrent Operating Assets
6.76 11 9.75 9.10 6.57 6.04 6.98 5.56 5.22 4.96
Other Noncurrent Nonoperating Assets
- - - - - - - 0.00 0.00 0.00
Total Liabilities & Shareholders' Equity
635 569 534 399 369 361 293 264 235 229
Total Liabilities
410 370 324 330 305 302 298 268 251 252
Total Current Liabilities
179 103 105 156 132 129 124 59 62 53
Accounts Payable
3.48 3.97 4.87 3.93 4.45 1.95 3.61 2.60 1.25 2.86
Accrued Expenses
9.67 4.32 6.77 8.36 8.38 6.46 7.47 9.92 12 6.96
Current Deferred Revenue
3.32 1.99 1.68 2.06 2.61 3.10 3.37 2.74 2.19 2.05
Current Employee Benefit Liabilities
11 8.09 5.49 8.25 6.44 7.24 7.30 4.57 4.83 4.02
Other Current Liabilities
122 82 84 85 64 64 56 40 42 37
Other Current Nonoperating Liabilities
- - - - - - - 0.00 0.00 0.00
Total Noncurrent Liabilities
230 266 220 174 173 173 174 209 188 199
Long-Term Debt
227 258 213 167 168 168 169 204 184 195
Other Noncurrent Operating Liabilities
2.88 - 0.02 0.02 5.12 4.92 5.18 4.36 4.03 3.81
Other Noncurrent Nonoperating Liabilities
- - - - - - - 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
225 199 210 70 64 59 -4.70 -4.00 -16 -23
Total Preferred & Common Equity
225 199 210 70 64 59 -4.70 -4.00 -16 -23
Total Common Equity
225 199 210 70 64 59 -4.70 -4.00 -16 -23
Common Stock
1,230 1,332 1,347 1,356 1,377 1,385 1,393 1,405 1,408 1,410
Retained Earnings
-1,010 -1,136 -1,140 -1,285 -1,314 -1,323 -1,396 -1,409 -1,423 -1,432
Accumulated Other Comprehensive Income / (Loss)
5.30 3.05 2.95 -1.50 1.25 -3.63 -2.04 -0.53 -0.68 -0.99

Annual Metrics And Ratios for Cardlytics

This table displays calculated financial ratios and metrics derived from Cardlytics' official financial filings.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
0.00 0.00 21,411,500.00 25,711,713.00 27,464,399.00 33,269,151.00 33,165,847.00 39,254,146.00 - 54,056,548.00
DEI Adjusted Shares Outstanding
0.00 0.00 21,411,500.00 25,711,713.00 27,464,399.00 33,269,151.00 33,165,847.00 39,254,146.00 - 54,056,548.00
DEI Earnings Per Adjusted Shares Outstanding
0.00 0.00 -2.48 -0.67 -2.02 -3.86 -14.03 -3.43 - -1.91
Growth Metrics
- - - - - - - - - -
Revenue Growth
0.00% 15.55% 15.59% 39.65% -11.19% 42.93% 11.76% 3.57% -10.00% -16.18%
EBITDA Growth
0.00% 101.19% -6,129.96% 71.69% -179.01% -121.49% -466.38% 75.84% -78.13% 60.16%
EBIT Growth
0.00% 83.60% -336.57% 66.66% -215.58% -136.50% -274.72% 71.48% -48.65% 51.43%
NOPAT Growth
0.00% 69.59% -139.29% 57.66% -211.24% -127.36% -273.39% 70.36% -44.10% 47.92%
Net Income Growth
0.00% 74.05% -170.06% 67.68% -223.27% -131.97% -261.89% 71.05% -40.54% 45.33%
EPS Growth
0.00% 75.80% 64.50% 74.19% 0.00% 0.00% 0.00% 73.49% -5.96% 50.13%
Operating Cash Flow Growth
0.00% 31.99% 14.06% 160.32% -166.32% -407.02% -39.93% 99.66% -4,669.73% 205.28%
Free Cash Flow Firm Growth
0.00% 0.00% -23.93% 72.64% -206.71% -1,769.42% 100.79% -1,570.65% 31.85% 105.25%
Invested Capital Growth
0.00% 0.00% 65.18% -0.26% -2.23% 1,594.76% -50.80% -4.81% -27.45% -34.01%
Revenue Q/Q Growth
0.00% 0.00% 6.02% 11.36% -1.17% 9.41% -2.47% 2.20% -5.17% -7.13%
EBITDA Q/Q Growth
0.00% 0.00% -33.34% 50.68% 11.16% -7.04% -767.80% 73.19% 28.72% 23.80%
EBIT Q/Q Growth
0.00% 0.00% -22.23% 46.48% -15.05% -11.44% -352.93% 67.75% 30.44% 7.53%
NOPAT Q/Q Growth
0.00% 0.00% -26.66% 41.05% -15.84% -9.16% -400.02% 67.34% 32.61% 2.13%
Net Income Q/Q Growth
0.00% 0.00% -16.49% 46.65% -22.57% -4.10% -370.82% 67.32% 31.05% 6.62%
EPS Q/Q Growth
0.00% 0.00% -105.15% 35.14% 0.00% 0.00% 0.00% 0.00% 0.00% 9.72%
Operating Cash Flow Q/Q Growth
0.00% 0.00% 4.22% 330.39% 16.63% -19.07% -30.34% 98.86% 0.51% 1,353.71%
Free Cash Flow Firm Q/Q Growth
0.00% 0.00% 0.00% 46.01% -5.96% -1.79% 105.49% -414.57% -53.71% 120.16%
Invested Capital Q/Q Growth
0.00% 0.00% 28.41% 21.24% 10.82% 1.36% -52.72% -23.41% -2.96% -13.32%
Profitability Metrics
- - - - - - - - - -
Gross Margin
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin
-52.25% 0.54% -28.05% -5.69% -17.86% -27.68% -140.29% -32.73% -64.78% -28.57%
Operating Margin
-49.84% -13.12% -27.15% -8.23% -28.85% -45.90% -153.34% -43.88% -70.25% -43.65%
EBIT Margin
-61.63% -8.75% -33.03% -7.89% -28.02% -46.37% -155.47% -42.81% -70.70% -40.97%
Profit (Net Income) Margin
-67.09% -15.07% -35.20% -8.15% -29.65% -48.13% -155.85% -43.56% -68.02% -44.36%
Tax Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 94.24% 99.69% 100.00% 100.00% 100.00%
Interest Burden Percent
108.87% 172.26% 106.56% 103.30% 105.82% 110.14% 100.55% 101.76% 96.21% 108.29%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% -101.86% -91.92% -31.28% -98.59% -25.26% -66.95% -30.83% -52.79% -39.39%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% -144.78% -307.91% -22.76% -82.80% 25.47% -594.55% -60.29% -86.24% -60.99%
Return on Net Nonoperating Assets (RNNOA)
0.00% 422.56% -175.12% 13.72% 61.70% -5.06% -36.17% -46.94% -132.08% -286.63%
Return on Equity (ROE)
0.00% 320.70% -267.04% -17.56% -36.89% -30.33% -103.13% -77.77% -184.88% -326.02%
Cash Return on Invested Capital (CROIC)
0.00% -301.86% -141.08% -31.02% -96.34% -202.98% 1.13% -25.89% -20.97% 1.58%
Operating Return on Assets (OROA)
0.00% -11.32% -39.12% -8.78% -16.19% -14.69% -47.48% -20.92% -40.70% -28.18%
Return on Assets (ROA)
0.00% -19.49% -41.68% -9.07% -17.14% -15.25% -47.60% -21.29% -39.16% -30.51%
Return on Common Equity (ROCE)
0.00% 5,463.68% 1,053.42% -17.56% -36.89% -30.33% -103.13% -77.77% -184.88% -326.02%
Return on Equity Simple (ROE_SIMPLE)
0.00% 9.41% -102.05% -11.97% -35.26% -18.61% -219.87% 0.00% -270.46% 0.00%
Net Operating Profit after Tax (NOPAT)
-39 -12 -29 -12 -38 -86 -320 -95 -137 -71
NOPAT Margin
-34.89% -9.18% -19.01% -5.76% -20.20% -32.13% -107.34% -30.71% -49.17% -30.55%
Net Nonoperating Expense Percent (NNEP)
0.00% 42.92% 215.99% -8.52% -15.79% -50.74% 527.59% 29.46% 33.45% 21.60%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - -73.22% -24.21% -48.26% -35.21%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
18.93% 15.42% 22.72% 17.45% 24.90% 24.79% 27.28% 19.02% 20.30% 20.26%
R&D to Revenue
12.32% 9.32% 10.76% 5.56% 9.38% 14.27% 18.23% 16.61% 17.83% 17.05%
Operating Expenses to Revenue
149.84% 113.12% 127.15% 108.23% 128.85% 145.90% 253.34% 143.88% 170.25% 143.65%
Earnings before Interest and Taxes (EBIT)
-70 -11 -50 -17 -52 -124 -464 -132 -197 -96
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-59 0.70 -42 -12 -33 -74 -419 -101 -180 -67
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
0.00 0.00 4.46 11.28 24.94 3.18 0.91 2.68 2.69 0.00
Price to Tangible Book Value (P/TBV)
0.00 0.00 4.64 11.62 26.06 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
0.62 0.54 1.54 7.68 20.98 8.23 0.64 1.17 0.68 0.27
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 12.87 6.16 39.04 100.43 3.35 0.94 1.75 1.54 1.55
Enterprise Value to Revenue (EV/Rev)
0.00 2.32 1.59 7.18 20.34 8.05 0.99 1.71 1.21 0.95
Enterprise Value to EBITDA (EV/EBITDA)
0.00 431.37 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 131.94 0.00 0.00 0.00 0.00 0.00 23.94
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 54.52 0.00 0.00 77.84
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
0.00 -4.65 0.90 0.00 1.11 0.27 1.07 1.91 3.05 -32.10
Long-Term Debt to Equity
0.00 -4.65 0.90 0.00 1.11 0.27 1.07 1.91 2.40 -32.10
Financial Leverage
0.00 -2.92 0.57 -0.60 -0.75 -0.20 0.06 0.78 1.53 4.70
Leverage Ratio
0.00 -8.23 6.41 1.94 2.15 1.99 2.17 3.65 4.72 10.69
Compound Leverage Factor
0.00 -14.17 6.83 2.00 2.28 2.19 2.18 3.72 4.54 11.57
Debt to Total Capital
0.00% 127.36% 47.33% 0.03% 52.54% 21.07% 51.65% 65.64% 75.32% 103.22%
Short-Term Debt to Total Capital
0.00% 0.10% 0.02% 0.02% 0.00% 0.00% 0.00% 0.00% 16.17% 0.00%
Long-Term Debt to Total Capital
0.00% 127.27% 47.31% 0.01% 52.54% 21.07% 51.65% 65.64% 59.15% 103.22%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 438.84% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
0.00% -466.20% 52.67% 99.97% 47.46% 78.93% 48.35% 34.36% 24.68% -3.22%
Debt to EBITDA
0.00 81.33 -1.11 0.00 -5.21 -2.49 -0.54 -2.54 -1.18 -3.14
Net Debt to EBITDA
0.00 51.00 -0.17 8.74 3.57 0.66 -0.25 -1.64 -0.82 -2.40
Long-Term Debt to EBITDA
0.00 81.27 -1.10 0.00 -5.21 -2.49 -0.54 -2.54 -0.93 -3.14
Debt to NOPAT
0.00 -4.76 -1.63 0.00 -4.61 -2.15 -0.71 -2.71 -1.56 -2.93
Net Debt to NOPAT
0.00 -2.99 -0.25 8.62 3.16 0.57 -0.32 -1.74 -1.08 -2.25
Long-Term Debt to NOPAT
0.00 -4.76 -1.63 0.00 -4.61 -2.15 -0.71 -2.71 -1.23 -2.93
Altman Z-Score
0.00 -2.05 -1.08 11.17 8.46 1.64 -3.52 -2.33 -5.14 -6.79
Noncontrolling Interest Sharing Ratio
0.00% -1,603.70% 494.48% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
0.00 1.77 2.40 2.50 4.74 1.10 1.00 1.31 1.19 1.75
Quick Ratio
0.00 1.72 1.93 2.42 4.67 1.07 0.97 1.27 1.16 1.70
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
0.00 -35 -44 -12 -37 -690 5.42 -80 -54 2.86
Operating Cash Flow to CapEx
-1,314.11% -1,392.69% -259.53% 104.26% -75.67% -309.89% -404.96% -1.49% -45.72% 58.86%
Free Cash Flow to Firm to Interest Expense
0.00 -4.31 -13.47 -21.94 -12.10 -54.88 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
-5.27 -2.68 -5.82 20.91 -2.49 -3.07 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
-5.67 -2.88 -8.06 0.85 -5.79 -4.06 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.00 1.29 1.18 1.11 0.58 0.32 0.31 0.49 0.58 0.69
Accounts Receivable Turnover
0.00 2.54 2.70 2.88 2.17 2.62 2.52 2.51 2.39 2.43
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 17.81 17.17 17.16 13.28 21.25 34.74 66.93 94.04 103.06
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 143.48 135.39 126.54 167.88 139.20 145.04 145.24 152.83 150.20
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 143.48 135.39 126.54 167.88 139.20 145.04 145.24 152.83 150.20
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
0.00 24 39 39 38 642 316 300 218 144
Invested Capital Turnover
0.00 11.09 4.84 5.43 4.88 0.79 0.62 1.00 1.07 1.29
Increase / (Decrease) in Invested Capital
0.00 24 15 -0.10 -0.86 604 -326 -15 -82 -74
Enterprise Value (EV)
0.00 302 239 1,512 3,802 2,150 296 527 337 222
Market Capitalization
70 70 232 1,616 3,921 2,199 192 362 189 62
Book Value per Share
$0.00 ($64.61) $2.43 $5.57 $5.72 $20.76 $6.38 $3.43 $1.38 ($0.12)
Tangible Book Value per Share
$0.00 ($64.91) $2.33 $5.41 $5.48 ($5.73) ($6.47) ($5.15) ($2.64) ($2.51)
Total Capital
0.00 45 99 143 331 875 438 392 284 202
Total Debt
0.00 57 47 0.04 174 184 226 258 214 209
Total Long-Term Debt
0.00 57 47 0.01 174 184 226 258 168 209
Net Debt
0.00 36 7.09 -105 -119 -49 104 166 148 160
Capital Expenditures (CapEx)
2.47 1.59 7.32 11 10 12 13 12 19 16
Debt-free, Cash-free Net Working Capital (DFCFNWC)
0.00 11 33 13 11 -202 -121 -39 9.30 10
Debt-free Net Working Capital (DFNWC)
0.00 33 72 117 304 31 1.10 53 75 59
Net Working Capital (NWC)
0.00 32 72 117 304 31 1.10 53 29 59
Net Nonoperating Expense (NNE)
36 7.67 24 5.02 18 43 145 40 52 32
Net Nonoperating Obligations (NNO)
0.00 36 -13 -105 -119 -49 104 166 148 150
Total Depreciation and Amortization (D&A)
11 12 7.51 4.63 19 50 45 31 16 29
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 8.65% 21.80% 6.07% 5.87% -75.69% -40.49% -12.63% 3.34% 4.36%
Debt-free Net Working Capital to Revenue
0.00% 24.96% 48.09% 55.77% 162.83% 11.75% 0.37% 17.07% 26.91% 25.24%
Net Working Capital to Revenue
0.00% 24.92% 48.08% 55.76% 162.83% 11.75% 0.37% 17.07% 10.43% 25.24%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
($32.48) ($7.86) ($2.79) ($0.72) ($2.04) $0.00 ($13.92) ($3.69) ($3.91) ($1.95)
Adjusted Weighted Average Basic Shares Outstanding
2.36M 3.23M 22.50M 26.70M 27.90M 0.00 33.42M 36.49M 48.36M 53.11M
Adjusted Diluted Earnings per Share
($32.48) ($7.86) ($2.79) ($0.72) ($2.04) $0.00 $0.00 $0.00 ($3.91) ($1.95)
Adjusted Weighted Average Diluted Shares Outstanding
2.36M 3.23M 22.50M 26.70M 27.90M 0.00 33.61M 44.11M 48.36M 53.11M
Adjusted Basic & Diluted Earnings per Share
($32.48) ($7.86) ($2.79) ($0.72) ($2.04) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
2.36M 3.23M 19.06M 23.75M 27.21M 0.00 33.61M 44.11M 52.09M 55.05M
Normalized Net Operating Profit after Tax (NOPAT)
-39 -12 -29 -12 -38 -86 -3.14 -46 -45 -30
Normalized NOPAT Margin
-34.89% -9.18% -19.01% -5.76% -20.20% -32.13% -1.05% -14.75% -16.07% -12.90%
Pre Tax Income Margin
-67.09% -15.07% -35.20% -8.15% -29.65% -51.07% -156.33% -43.56% -68.02% -44.36%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
-11.27 -1.38 -15.25 -30.28 -17.18 -9.86 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
-6.38 -1.45 -8.78 -22.13 -12.38 -6.83 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
-11.67 -1.58 -17.49 -50.34 -20.48 -10.85 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
-6.78 -1.65 -11.02 -42.18 -15.68 -7.82 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
-2.21% -13.58% -3.67% -1.14% 0.00% -0.15% -8.63% 0.00% -0.16% 0.00%

Quarterly Metrics And Ratios for Cardlytics

This table displays calculated financial ratios and metrics derived from Cardlytics' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
44,109,102.00 48,783,041.00 49,840,104.00 - 52,085,224.00 52,502,390.00 53,236,901.00 54,056,548.00 55,054,268.00 57,605,677.00 5,888,716.00
DEI Adjusted Shares Outstanding
44,109,102.00 48,783,041.00 49,840,104.00 - 52,085,224.00 52,502,390.00 53,236,901.00 54,056,548.00 55,054,268.00 5,760,568.00 5,888,716.00
DEI Earnings Per Adjusted Shares Outstanding
-0.55 -0.09 -2.91 - -0.26 -0.18 -1.37 -0.15 -0.08 -2.58 -1.52
Growth Metrics
- - - - - - - - - - -
Revenue Growth
5.09% -9.21% -15.12% -17.01% -16.53% -9.17% -22.41% -24.19% -39.19% -36.46% -29.98%
EBITDA Growth
-174.25% 42.47% -746.38% 78.39% 92.84% 99.71% 53.39% 111.40% -323.28% -118.15% 99.46%
EBIT Growth
-272.27% 31.49% -523.41% 86.10% 63.81% 53.29% 50.83% 56.02% -17.58% -28.06% 92.48%
NOPAT Growth
-230.68% 34.99% -619.28% 91.92% 51.31% 19.12% 53.65% 26.71% 25.56% 43.14% 91.84%
Net Income Growth
-278.39% 81.89% -505.78% 84.54% 45.29% -118.06% 49.94% 47.08% 66.27% -60.25% 87.69%
EPS Growth
-240.00% 86.57% -360.32% 87.10% 0.00% -100.00% 53.10% 58.33% 0.00% 0.00% 0.00%
Operating Cash Flow Growth
-75.05% -22.99% 16.00% 1.53% 61.93% -72.34% 27.15% 336.72% 15.87% -801.80% -434.98%
Free Cash Flow Firm Growth
-109.51% -86.52% -75.57% 234.85% 468.09% 334.14% -83.59% -8.87% -41.70% -35.77% 68.52%
Invested Capital Growth
6.07% -9.98% -42.75% -27.45% -39.03% -37.28% -26.11% -34.01% -37.88% -37.96% -14.61%
Revenue Q/Q Growth
-24.18% 3.00% -3.70% 10.35% -23.73% 2.18% -17.74% 7.81% -38.82% 7.47% -10.85%
EBITDA Q/Q Growth
82.50% 49.07% -1,544.78% 85.26% 83.42% 99.42% -263,600.00% 101.26% -715.29% 88.19% 43.45%
EBIT Q/Q Growth
76.54% 33.01% -814.55% 90.33% 38.92% 35.91% -862.75% 91.35% -63.31% 47.13% 2.71%
NOPAT Q/Q Growth
77.82% 30.73% -839.45% 94.40% -33.67% 9.16% -438.38% 91.15% -35.77% 34.24% 0.37%
Net Income Q/Q Growth
75.93% 82.46% -3,310.43% 89.26% 14.80% 30.11% -682.86% 88.65% 45.70% -232.05% 39.86%
EPS Q/Q Growth
79.93% 83.93% -3,122.22% 87.59% 0.00% 30.77% -655.56% 88.97% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth
-700.44% 125.14% -68.73% 115.09% -325.11% 118.27% 43.76% 638.78% -143.37% -52.38% 31.38%
Free Cash Flow Firm Q/Q Growth
34.58% 177.76% 120.36% 20.31% 78.57% -6.88% -91.67% 568.08% 14.23% 2.86% -75.07%
Invested Capital Q/Q Growth
23.36% -2.67% -37.73% -2.96% 3.67% 0.12% -26.64% -13.32% -2.41% -0.02% 0.96%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin
-23.98% -11.86% -202.50% -27.05% -2.06% -0.04% -121.64% 1.42% -14.31% -1.57% -1.00%
Operating Margin
-33.76% -22.71% -221.52% -11.24% -19.70% -20.22% -132.33% -10.86% -24.11% -14.75% -16.49%
EBIT Margin
-34.69% -22.56% -214.30% -18.78% -15.04% -11.60% -135.82% -10.89% -29.08% -14.31% -15.61%
Profit (Net Income) Margin
-35.91% -6.11% -216.51% -21.07% -23.54% -14.68% -139.67% -14.71% -13.05% -40.33% -27.21%
Tax Burden Percent
100.00% 100.00% 100.00% 100.00% 128.73% 100.00% 100.00% 100.00% 32.47% 171.80% 120.47%
Interest Burden Percent
103.49% 27.09% 101.03% 112.19% 121.56% 126.47% 102.84% 135.00% 138.26% 164.12% 144.69%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
-20.51% -12.75% -147.52% -8.44% -12.34% -12.84% -119.13% -9.80% -19.45% -10.70% -13.20%
ROIC Less NNEP Spread (ROIC-NNEP)
-26.26% -8.43% -173.11% -14.67% -15.64% -13.05% -134.17% -12.48% -18.60% -17.54% -16.27%
Return on Net Nonoperating Assets (RNNOA)
-17.57% -5.96% -188.90% -22.48% -19.82% -15.45% -672.17% -58.63% -94.79% -133.03% 196.79%
Return on Equity (ROE)
-38.08% -18.71% -336.42% -30.92% -32.16% -28.29% -791.30% -68.44% -114.25% -143.73% 183.60%
Cash Return on Invested Capital (CROIC)
-39.08% -19.32% -11.47% -20.97% 5.37% 2.01% -7.26% 1.58% 8.90% 10.64% 0.38%
Operating Return on Assets (OROA)
-17.30% -11.80% -121.61% -10.81% -8.57% -6.90% -98.57% -7.49% -19.40% -9.12% -10.54%
Return on Assets (ROA)
-17.90% -3.20% -122.86% -12.13% -13.40% -8.73% -101.36% -10.12% -8.71% -25.72% -18.36%
Return on Common Equity (ROCE)
-38.08% -18.71% -336.42% -30.92% -32.16% -28.29% -791.30% -68.44% -114.25% -143.73% 183.60%
Return on Equity Simple (ROE_SIMPLE)
-86.67% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-16 -11 -104 -5.82 -7.78 -8.95 -48 -4.27 -5.79 -3.81 -3.79
NOPAT Margin
-23.63% -15.89% -155.07% -7.87% -13.79% -14.15% -92.63% -7.60% -16.88% -10.33% -11.54%
Net Nonoperating Expense Percent (NNEP)
5.75% -4.32% 25.60% 6.23% 3.30% 0.21% 15.03% 2.67% -0.86% 6.83% 3.07%
Return On Investment Capital (ROIC_SIMPLE)
-3.42% -2.56% -35.66% -2.05% -2.80% -3.28% -22.96% -2.11% -2.89% -2.26% -2.21%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
21.43% 23.19% 18.01% 18.61% 22.93% 20.40% 20.86% 17.35% 24.13% 21.30% 21.56%
R&D to Revenue
19.30% 19.34% 19.68% 13.37% 18.21% 17.86% 16.91% 14.20% 18.74% 15.02% 11.29%
Operating Expenses to Revenue
133.76% 122.71% 321.52% 111.24% 119.70% 120.22% 232.33% 110.86% 124.11% 114.75% 116.49%
Earnings before Interest and Taxes (EBIT)
-23 -16 -144 -14 -8.49 -7.34 -71 -6.11 -9.98 -5.28 -5.13
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-16 -8.26 -136 -20 -1.16 -0.02 -63 0.80 -4.91 -0.58 -0.33
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
3.21 1.91 2.29 2.69 1.48 1.47 0.00 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
2.05 1.31 0.54 0.68 0.35 0.32 0.52 0.27 0.27 0.14 0.10
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
2.18 1.53 1.40 1.54 1.14 1.12 1.81 1.55 1.44 1.30 1.28
Enterprise Value to Revenue (EV/Rev)
2.59 1.80 1.07 1.21 0.96 0.95 1.19 0.95 0.96 0.96 1.03
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 123.00 0.00 0.00 23.94 19.53 342.55 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 16.02 43.14 0.00 77.84 12.40 9.35 313.51
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
1.34 1.06 3.18 3.05 3.34 3.65 -45.63 -32.10 -51.01 -11.52 -8.46
Long-Term Debt to Equity
1.33 1.05 2.49 2.40 2.62 2.87 -35.84 -32.10 -51.01 -11.52 -8.46
Financial Leverage
0.67 0.71 1.09 1.53 1.27 1.18 5.01 4.70 5.10 7.59 -12.10
Leverage Ratio
2.91 2.62 3.51 4.72 3.56 3.33 10.65 10.69 10.53 13.96 -18.80
Compound Leverage Factor
3.01 0.71 3.54 5.30 4.33 4.21 10.95 14.43 14.56 22.90 -27.20
Debt to Total Capital
57.34% 51.38% 76.10% 75.32% 76.95% 78.50% 102.24% 103.22% 102.00% 109.50% 113.41%
Short-Term Debt to Total Capital
0.45% 0.53% 16.51% 16.17% 16.52% 16.85% 21.94% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
56.89% 50.85% 59.59% 59.15% 60.43% 61.64% 80.30% 103.22% 102.00% 109.50% 113.41%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
42.66% 48.62% 23.90% 24.68% 23.05% 21.50% -2.24% -3.22% -2.00% -9.50% -13.41%
Debt to EBITDA
-1.92 -1.67 -0.88 -1.18 -1.41 -1.34 -2.45 -3.14 -2.90 -2.49 -14.31
Net Debt to EBITDA
-1.22 -1.13 -0.61 -0.82 -1.06 -1.05 -1.95 -2.40 -2.05 -2.11 -12.11
Long-Term Debt to EBITDA
-1.91 -1.65 -0.69 -0.93 -1.10 -1.05 -1.93 -3.14 -2.90 -2.49 -14.31
Debt to NOPAT
-2.24 -1.95 -1.09 -1.56 -1.66 -1.67 -2.95 -2.93 -2.95 -2.78 -8.22
Net Debt to NOPAT
-1.42 -1.33 -0.76 -1.08 -1.26 -1.30 -2.34 -2.25 -2.08 -2.36 -6.96
Long-Term Debt to NOPAT
-2.22 -1.93 -0.86 -1.23 -1.31 -1.31 -2.31 -2.93 -2.95 -2.78 -8.22
Altman Z-Score
-1.10 -1.59 -4.58 -3.61 -4.07 -4.22 -6.28 -5.76 -6.35 -7.49 -7.81
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
2.13 1.77 1.18 1.19 1.19 1.16 1.14 1.75 2.17 1.62 1.82
Quick Ratio
2.04 1.71 1.13 1.16 1.15 1.11 1.09 1.70 2.12 1.58 1.74
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-37 29 64 77 137 126 10 70 80 82 20
Operating Cash Flow to CapEx
-371.12% 91.17% 26.35% 67.16% -163.44% 26.30% 39.45% 508.80% -244.88% -408.41% -268.26%
Free Cash Flow to Firm to Interest Expense
-45.41 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
-21.51 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
-27.31 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.50 0.52 0.57 0.58 0.57 0.59 0.73 0.69 0.67 0.64 0.67
Accounts Receivable Turnover
2.98 2.92 2.70 2.39 2.54 2.61 2.50 2.43 2.56 2.27 2.29
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
81.58 94.19 100.30 94.04 99.45 97.28 99.42 103.06 100.34 94.86 95.50
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
122.56 124.95 135.41 152.83 143.78 139.85 146.01 150.20 142.78 160.52 159.53
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
122.56 124.95 135.41 152.83 143.78 139.85 146.01 150.20 142.78 160.52 159.53
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
371 361 225 218 226 226 166 144 140 140 142
Invested Capital Turnover
0.87 0.80 0.95 1.07 0.90 0.91 1.29 1.29 1.15 1.04 1.14
Increase / (Decrease) in Invested Capital
21 -40 -168 -82 -145 -134 -59 -74 -86 -86 -24
Enterprise Value (EV)
809 551 314 337 257 254 300 222 202 182 182
Market Capitalization
639 401 159 189 95 86 129 62 58 26 17
Book Value per Share
$4.51 $4.31 $1.40 $1.38 $1.23 $1.12 ($0.09) ($0.12) ($0.07) ($0.28) ($3.91)
Tangible Book Value per Share
($3.11) ($2.59) ($2.70) ($2.64) ($2.67) ($2.74) ($2.77) ($2.51) ($2.40) ($2.48) ($25.24)
Total Capital
467 432 292 284 278 273 210 202 200 168 172
Total Debt
268 222 222 214 214 214 215 209 204 184 195
Total Long-Term Debt
266 220 174 168 168 168 169 209 204 184 195
Net Debt
170 151 155 148 162 168 171 160 144 156 165
Capital Expenditures (CapEx)
4.75 4.86 5.26 4.44 4.10 4.66 4.46 2.56 2.30 2.11 2.20
Debt-free, Cash-free Net Working Capital (DFCFNWC)
20 12 8.58 9.30 19 21 19 10 9.37 11 13
Debt-free Net Working Capital (DFNWC)
118 83 76 75 71 67 63 59 69 39 43
Net Working Capital (NWC)
116 81 27 29 25 21 17 59 69 39 43
Net Nonoperating Expense (NNE)
8.30 -6.81 41 9.77 5.50 0.33 24 3.98 -1.31 11 5.15
Net Nonoperating Obligations (NNO)
172 151 155 148 162 168 171 150 144 156 165
Total Depreciation and Amortization (D&A)
7.24 7.46 7.91 -6.12 7.33 7.32 7.38 6.91 5.07 4.70 4.81
Debt-free, Cash-free Net Working Capital to Revenue
6.41% 3.85% 2.93% 3.34% 7.06% 7.71% 7.61% 4.36% 4.44% 5.62% 7.67%
Debt-free Net Working Capital to Revenue
37.69% 27.18% 25.75% 26.91% 26.55% 25.27% 25.11% 25.24% 32.76% 20.38% 24.69%
Net Working Capital to Revenue
37.03% 26.43% 9.34% 10.43% 9.35% 7.98% 6.77% 25.24% 32.76% 20.38% 24.69%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.56) ($0.09) ($2.90) ($0.36) ($0.26) ($0.18) ($1.36) ($0.15) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding
43.25M 49.06M 50.03M 48.36M 51.86M 52.75M 53.49M 53.11M 54.90M 5.76M 5.90M
Adjusted Diluted Earnings per Share
($0.56) ($0.09) ($2.90) ($0.36) ($0.26) ($0.18) ($1.36) ($0.15) $0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding
43.25M 49.06M 50.03M 48.36M 51.86M 52.75M 53.49M 53.11M 54.90M 5.76M 5.90M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
48.78M 49.84M 50.82M 52.09M 52.50M 53.24M 54.06M 55.05M 57.61M 5.89M 6.10M
Normalized Net Operating Profit after Tax (NOPAT)
-16 -11 -12 -5.82 -12 -8.81 -6.78 -4.27 -5.79 -3.81 -3.79
Normalized NOPAT Margin
-23.63% -15.73% -17.69% -7.87% -20.42% -13.93% -13.04% -7.60% -16.88% -10.33% -11.54%
Pre Tax Income Margin
-35.91% -6.11% -216.51% -21.07% -18.28% -14.68% -139.67% -14.71% -40.21% -23.48% -22.59%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
-28.64 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
-19.51 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
-34.44 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
-25.31 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% -0.09% -0.09% -0.16% 0.00% -0.06% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Cardlytics’ financial statements show cost reductions and lower losses, but the company remains under significant financial pressure. Q2 2026 revenue increased sequentially to $36.9 million from $34.3 million in Q1, while total operating expenses declined slightly to $42.3 million from $42.6 million. However, revenue was still down approximately 36.5% from the restated $58.0 million reported in Q2 2025.

  • Operating losses improved sequentially. Q2 2026 operating loss was $5.4 million, compared with an $8.3 million loss in Q1 2026. This improvement reflects the quarter’s higher revenue and lower selling, general and administrative, marketing, and research and development expenses.
  • The company has substantially reduced expenses from 2025 levels. Q2 2026 SG&A, marketing, and research and development expenses totaled approximately $20.0 million, down from roughly $32.0 million in Q2 2025.
  • Debt repayments continued. Cardlytics repaid $20.1 million of debt in Q2 2026 after repaying $10.0 million in Q1. Long-term debt declined to $184.4 million from $204.2 million at the end of Q1.
  • Q2 investing cash flow was strongly positive. Investing activities provided $20.9 million, contrasting with cash outflows in the prior quarters. The data does not specify the source of the proceeds, so investors should determine whether this was a recurring operating benefit or a one-time transaction.
  • Revenue showed a modest sequential recovery. Q2 revenue rose 7.5% from Q1 2026, but the business remains well below the $67.1 million reported in Q3 2024 and $73.0 million in Q4 2024.
  • Q2’s loss included a sizable discontinued-operations charge. The company reported a $6.2 million loss from discontinued operations, compared with $9.3 million of income from discontinued operations in Q1. This volatility makes consolidated earnings less representative of ongoing operations.
  • Cardlytics remains unprofitable. Q2 2026 consolidated net loss was $14.9 million, or approximately $2.59 per basic share based on the reported weighted-average share count. Continuing operations lost $8.7 million.
  • Operating cash flow has deteriorated. Cash used in operations increased to $8.6 million in Q2 2026 from $5.6 million in Q1. This compares with positive operating cash flow of $13.0 million in Q4 2025 and $4.4 million in Q2 2024, indicating that recent cost reductions have not yet produced sustainable cash generation.
  • Liquidity has tightened sharply. Cash and equivalents declined to $28.0 million at June 30, 2026, from $35.7 million at the end of Q1 and $46.7 million a year earlier. Q2’s $7.6 million cash reduction followed a $13.0 million decline in Q1.
  • The balance sheet is highly leveraged and has negative equity. Long-term debt was $184.4 million, while total liabilities were $250.8 million. Total shareholders’ equity was negative $16.0 million, compared with positive equity of $58.7 million in Q2 2025. Goodwill and intangible assets together represented approximately $127.0 million of assets, creating additional impairment risk if operating performance weakens.

Overall, Cardlytics is showing progress in reducing its cost base and repaying debt, but those improvements are being offset by declining revenue, recurring net losses, negative operating cash flow, shrinking liquidity, and a balance sheet with negative equity. The key indicators for investors are whether revenue can stabilize above current levels and whether management can return the business to consistently positive operating cash flow before available liquidity becomes a greater concern.

11/17/26 12:30 PM ETAI Generated. May Contain Errors.

Cardlytics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Cardlytics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Cardlytics' net income appears to be on a downward trend, with a most recent value of -$103.49 million in 2025, falling from -$75.70 million in 2016. The previous period was -$189.30 million in 2024. View Cardlytics' forecast to see where analysts expect Cardlytics to go next.

Cardlytics' total operating income in 2025 was -$101.82 million, based on the following breakdown:
  • Total Gross Profit: $233.27 million
  • Total Operating Expenses: $335.09 million

Over the last 9 years, Cardlytics' total revenue changed from $112.82 million in 2016 to $233.27 million in 2025, a change of 106.8%.

In the past 12 quarters, Cardlytics' cash and equivalents has ranged from $28.04 million in Q2 2026 to $97.77 million in Q1 2024, and is currently $29.95 million as of their latest financial filing in Q3 2026.

Cardlytics had total debt of $208.92 million at the end of 2025, a 2.2% decrease from 2024, and none in 2016.

Over the last 9 years, Cardlytics' book value per share changed from 0.00 in 2016 to -0.12 in 2025.



Financial statements for NASDAQ:CDLX last updated on 11/5/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners